Medicenna Therapeutics Q3 2026 Earnings Results & Report

Medicenna Therapeutics EPS Results

• Actual EPS: -$0.05
• Consensus EPS: -$0.04
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

Medicenna Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Medicenna Therapeutics (OTCMKTS:MDNAF) is a Canadian clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s research is based on its Superkine platform, which is designed to modify cytokines—immune-signaling proteins—to improve their ability to stimulate anti-tumor immune responses while addressing limitations associated with conventional cytokine therapies.

Medicenna’s lead product candidate is MDNA11, a long-acting, beta-biased interleukin-2 (IL-2) agonist being developed for the treatment of advanced solid tumors. The therapy is intended to selectively activate immune cells involved in cancer control, including natural killer cells and tumor-reactive T cells. Medicenna has also developed MDNA55, an investigational targeted toxin designed to deliver an anti-cancer payload to cells expressing the interleukin-4 receptor, with a focus on difficult-to-treat brain tumors.

Founded in Canada, Medicenna conducts its research and clinical development activities through collaborations and clinical programs in North America and other relevant markets. Fahar Merchant, Ph.D., is the company’s co-founder and chief executive officer. Medicenna Therapeutics is headquartered in Vancouver, British Columbia, and its shares trade in Canada and on the U.S. over-the-counter market under the symbol MDNAF.